ライフサイエンスコーパス: heart transplantation

1 ventricular assist device implantation, and heart transplantation).

2 re were 33 069 patients (25% women) awaiting heart transplantation.

3 d transplanted vasculature in children after heart transplantation.

4 ) correlated with all-cause death, LVAD, and heart transplantation.

5 cedures in patients before and after lung or heart transplantation.

6 the overall level of immunosuppression after heart transplantation.

7 primary end point was all-cause mortality or heart transplantation.

8 apy can be used to support children awaiting heart transplantation.

9 erfusion injury in a rat model of kidney and heart transplantation.

10 as), and 2 were on amiodarone as a bridge to heart transplantation.

11 ations are common in patients after lung and heart transplantation.

12 tor of allograft tolerance in a rat model of heart transplantation.

13 revalence among patients that have undergone heart transplantation.

14 B cell repertoire to immunosuppression after heart transplantation.

15 c antibodies seem to impact graft outcome in heart transplantation.

16 ction in an immunocompetent patient prior to heart transplantation.

17 recovery, mechanical circulatory support or heart transplantation.

18 CMR) and early onset of microvasculopathy in heart transplantation.

19 om subjects undergoing LVAD placement and/or heart transplantation.

20 6 months, a proportion of 48% PPCMP received heart transplantation.

21 ension in 74 patients 13.5+/-6.7 years after heart transplantation.

22 HLA matching on graft survival in pediatric heart transplantation.

23 the major cause of late allograft loss after heart transplantation.

24 rt reducing the survival rates for pediatric heart transplantation.

25 t exercise test, 19 patients died or were re-heart transplantation.

26 of Toxoplasma serostatus on mortality after heart transplantation.

27 nt of available allografts were accepted for heart transplantation.

28 corporeal membrane oxygenation for bridge to heart transplantation.

29 vanced heart failure who were ineligible for heart transplantation.

30 lood correlates with acute rejection (AR) in heart transplantation.

31 ension in 74 patients 13.5+/-6.7 years after heart transplantation.

32 s two of the major clinical challenges after heart transplantation.

33 tion exists in patients undergoing emergency heart transplantation.

34 independent risk factors for mortality after heart transplantation.

35 27 (25%) patients died and 9 (8%) underwent heart transplantation.

36 profiles determine outcomes after emergency heart transplantation.

37 uent risk of the primary outcome of death or heart transplantation.

38 st 4C12 4 days before heterotopic allogeneic heart transplantation.

39 athy and should be routinely monitored after heart transplantation.

40 a risk score for rejection after orthotopic heart transplantation.

41 ted ventricular assist device as a bridge to heart transplantation.

42 ejection (AMR) is an important problem after heart transplantation.

43 primary endpoint was all-cause mortality or heart transplantation.

44 ned specifically for children as a bridge to heart transplantation.

45 l cause of long-term graft failure following heart transplantation.

46 iated with allograft rejection in kidney and heart transplantation.

47 reated rejection within 1 year of orthotopic heart transplantation.

48 and in research stratification in orthotopic heart transplantation.

49 w plasma cells readily detectable 50 d after heart transplantation.

50 ft survival and a major cause of death after heart transplantation.

51 act on cancer risk and total mortality after heart transplantation.

52 jection episodes within 1 year of orthotopic heart transplantation.

53 The primary end point was all-cause death or heart transplantation.

54 is still a leading cause of death late after heart transplantation.

55 nship between center volume and mortality in heart transplantation.

56 with sCVD who are undergoing evaluation for heart transplantation.

57 day mortality but better late survival after heart transplantation.

58 ith stroke in the perioperative period after heart transplantation.

59 nvolved in allograft rejection in kidney and heart transplantation.

60 improved graft survival in primary pediatric heart transplantation.

61 val has been primarily due to utilization of heart transplantation.

62 Supraventricular tachycardia is common after heart transplantation.

63 ion and cardiac allograft vasculopathy after heart transplantation.

64 ion, ventricular assist device placement, or heart transplantation.

65 arison to non-ACHD patients while listed for heart transplantation.

66 enocyte immunization in vivo, and allogeneic heart transplantation.

67 al and cardiomyocyte recovery from IRI after heart transplantation.

68 ents with heart failure, LVAD, or orthotopic heart transplantation.

69 s, 375 patients (26.6%) experienced death or heart transplantation.

70 ndent predictor of long-term mortality after heart transplantation.

71 A total of 2384 patients underwent heart transplantation.

72 e Achilles' heel of long-term survival after heart transplantation.

73 e frailty phenotype in patients referred for heart transplantation.

74 ct the outcomes for ACHD patients listed for heart transplantation.

75 RHF persists as a complication of pediatric heart transplantation.

76 s of ischemia-reperfusion injury (IRI) after heart transplantation.

77 ion between ASP and long-term mortality post-heart transplantation.

78 decompensated patients to permanent LVAD or heart transplantation.

79 ccurred in 5 patients: 3 underwent emergency heart transplantation, 1 had left ventricular assist dev

80 g transplantation, 13 liver, 6 kidney, and 2 heart transplantation; 11 probable or proven IPA, 11 pos

81 The 5-year incidence rates were 29% for heart transplantation, 12.1% non-SCD, 4.0% death from un

82 Patients with HF were more likely to undergo heart transplantation (15/142 versus 1/147; P<0.001) or

83 UK Renal Registry were linked for 1732 adult heart transplantations, 1996 to 2007.

84 of CMV replication (hazard ratio [HR] after heart transplantation, 2.60; 95% confidence interval [CI

85 pediatric (</= 18 years) patients listed for heart transplantation 2000-2011.

86 haring) for all adults listed for orthotopic heart transplantation (2000-2015) with a listed diagnosi

87 ardiographic normalization (30% and 27%) and heart transplantation (24% and 24%) were similar, the de

88 or ventricular assist device, 17 (16.3%) had heart transplantation, 25 (24%) died, and 62 (59.6%) sho

89 sive myocardial dysfunction causing death or heart transplantation (8 of 14 cases), frequent conducti

90 vanced heart failure who were ineligible for heart transplantation, a small, intrapericardial, centri

91 as of increased cardiac fibrosis years after heart transplantation, a substantial number of Y chromos

92 his study demonstrated a survival benefit of heart transplantation across all ranges of estimated don

93 myopathy (DCM) is the leading indication for heart transplantation after 1 year of age.

94 half of women with end-stage PPCPM received heart transplantation after 3 years of mechanical suppor

95 children and young adults being referred for heart transplantation after failed congenital heart surg

96 e end point was time to death or listing for heart transplantation after the CMR study.

97 ssociated with an increased risk of death or heart transplantation (all Ps<0.001).

98 rrhythmias, syncope, cardiomyopathy, angina, heart transplantation and coronary bypass grafts, corona

99 or pump failure or refractory VAs, including heart transplantation and durable mechanical circulatory

100 ents with end-stage heart failure undergoing heart transplantation and from apolipoprotein E-deficien

101 ssociated with increased all-cause mortality/heart transplantation and heart failure-related hospital

102 opies can be safely performed after lung and heart transplantation and in patients on the waiting lis

103 is common in patients with CHF referred for heart transplantation and is associated with adverse car

104 anced symptomatic heart failure referred for heart transplantation and is associated with increased m

105 By linking national heart transplantation and renal data, we have determined

106 t options for advanced heart failure include heart transplantation and ventricular assist device (VAD

107 on injury, immunological consequences during heart transplantations and also to study remodeling of t

108 terventions to improve cardiac function (eg, heart transplantation) and among patients examined over

109 entricular assist device, 21 (4.1%) received heart transplantation, and 37 (7.2%) died.

110 was used to estimate freedom from ICD shock, heart transplantation, and death.

111 term follow-up included all-cause mortality, heart transplantation, and implantation of a left ventri

112 Incidence of all-cause death, heart transplantation, and LVAD was independently relate

113 ection, cardiac allograft vasculopathy after heart transplantation, and potentially bronchiolitis obl

114 /- 0.6 procedures, 1-4), freedom from death, heart transplantation, and readmission for VT recurrence

115 CAV limits long-term survival after heart transplantation, and screening for CAV is performe

116 sex differences in mortality while awaiting heart transplantation, and the reason remains unclear.

117 r rabbit antithymocyte globulin (rATG) after heart transplantation, and there is currently wide varia

118 Nine patients underwent heart transplantation, and transplant-free survival to d

119 In heart transplantation, antibody-mediated rejection (AMR)

120 agnosis of myocarditis listed for orthotopic heart transplantation are younger, sicker, and recover m

121 proportion of patients with AHF who received heart transplantation at 1 year was 29% compared with 22

122 A total of 255 patients who underwent heart transplantation at the University Hospital Zurich

123 compatibility complex-mismatched heterotopic heart transplantation (BALB/c to C57BL/6) was performed.

124 from anthracyclines are often precluded from heart transplantation because of a history of cancer.

125 ed for all patients in England who underwent heart transplantation between 1995 and 2014.

126 d to identify patients undergoing orthotopic heart transplantation between 1998 and 2008.

127 onal registry CRISTAL for first single-organ heart transplantation between January 2010 and December

128 66) newly registered on the waiting list for heart transplantation between January 2010 and December

129 on class III/IV) referred for assessment for heart transplantation between November 2011 and April 20

130 To test these possibilities, we performed heart transplantation between outbred or inbred mice.

131 After heart transplantation, both JAK1/3 inhibitors reduced ea

132 therapy results in a high rate of successful heart transplantation but is associated with bleeding, i

133 ssion was examined in a model of heterotopic heart transplantation by microarray analyses and a uniqu

134 Heart transplantation can be performed using carefully s

135 Pediatric heart transplantation can have excellent outcomes with s

136 FM have an increased mortality and need for heart transplantation compared with those with NFM.

137 s study sought to investigate the benefit of heart transplantation compared with waiting while accoun

138 hy might be improved if the risk of death or heart transplantation could be predicted by risk factors

139 lt patients with severe systemic RV failure, heart transplantation currently remains the only long-te

140 ng to the International Society for Lung and Heart Transplantation definition, combining arterial oxy

141 gle-center analysis, 523 patients undergoing heart transplantation during 1996 to 2009 were stratifie

142 Of 45 941 adults listed for orthotopic heart transplantation during this period, we identified

143 Current immunosuppressive therapy after heart transplantation either generally suppresses the re

144 s for ventricular tachyarrhythmias (n=33) or heart transplantation for advanced heart failure (n=18 [

145 fluid (CSF) from a patient who had undergone heart transplantation for dilated cardiomyopathy 11 mont

146 illators (ICDs) for sudden death prevention, heart transplantation for end-stage failure, surgical my

147 7 nonobstructive patients (2.8%) did require heart transplantation for progression to end stage versu

148 ul when considering the immediate benefit of heart transplantation for status 2 candidates in stable

149 Long-term heart transplantation-free survival at 9 years was lower

150 were independently associated with long-term heart transplantation-free survival, regardless of the c

151 patients referred or on the waiting list for heart transplantation from March 2013 underwent frailty

152 edures in patients before and after lung and heart transplantation from May 1999 to September 2012 wa

153 Monkeys undergoing allogeneic heart transplantation given alemtuzumab were monitored f

154 edical management and the graft failure post-heart transplantation groups had higher 30-day survival

155 Heterotopic abdominal rat heart transplantation has been extensively used to inves

156 ities and are older because the criteria for heart transplantation has few absolute contraindications

157 The use of induction therapy in pediatric heart transplantation has increased.

158 The field of heart transplantation has seen significant progress in t

159 Several clinical risk factors for death and heart transplantation have been identified in patients w

160 munity and alloimmunity in a model of murine heart transplantation have clinical relevance to the kno

161 comes before and after listing for pediatric heart transplantation have not been assessed.

162 n, outcomes in patients with sCVD undergoing heart transplantation have not been well defined.

163 Status 2 candidates showed a benefit from heart transplantation; however, survival benefit was del

164 erally been considered a contraindication to heart transplantation; however, the data supporting this

165 Changes in heart transplantation (HT) donor and recipient demograph

166 e implantable cardioverter-defibrillator and heart transplantation (HT) in patients with hypertrophic

167 t that children with myocarditis who receive heart transplantation (HT) may be at higher risk of post

168 plantation (KT), liver transplantation (LT), heart transplantation (HT) or lung transplantation (LuT)

169 surveillance endomyocardial biopsy (EMB) in heart transplantation (HT) patients.

170 Maintenance steroid (MS) use in pediatric heart transplantation (HT) varies across centers.

171 tudy was to assess the survival benefit from heart transplantation (HT), defined as reduction in the

172 igens (HLAs) in patients being evaluated for heart transplantation (HT).

173 ) remains a leading cause of mortality after heart transplantation (HT).

174 to discuss future directions of research in heart transplantation (HT).

175 ransplant in-hospital mortality in pediatric heart transplantation (HT).

176 We assessed HRR after pediatric heart transplantation (HTx) and its prognostic use.

177 cophenolate mofetil (MMF) and steroids after heart transplantation (HTX) are rarely published.

178 Albuminuria in maintenance heart transplantation (HTx) is associated with poor rena

179 r assist devices (LVAD) as a bridge (BTT) to heart transplantation (HTX) may be limited by the format

180 Young adult heart transplantation (HTx) recipients experience high m

181 From 2005 to 2010, 77 consecutive heart transplantation (HTx) recipients were included.

182 Pediatric data on the impact of pre-heart transplantation (HTx) risk factors on early post-H

183 es of liver dysfunction, as a tool to assess heart transplantation (HTx) urgency in ambulatory patien

184 Among the various complications of heart transplantation (HTx), the vasculopathy of the all

185 Lactic acidosis (LA) frequently occurs after heart transplantation (HTx).

186 erated fibrotic remodeling in children after heart transplantation (HTx).

187 limitation in long-term graft survival after heart transplantation (HTx).

188 IFI) is associated with high mortality after heart transplantation (HTx).

189 xpand listing criteria for patients awaiting heart transplantation (HTx).

190 (2)) is widely used to select candidates for heart transplantation (HTx).

191 ause of graft failure and death 1 year after heart transplantation (HTx).

192 n important aspect for patient outcome after heart transplantation (HTX).

193 were collected from pediatric patients after heart transplantation (HTx, n=57), renal transplantation

194 Thrombosis was managed by heart transplantation in 11 patients (1 patient died 31

195 ed 704 adult patients treated with emergency heart transplantation in 15 Spanish centers between 2000

196 e exchange to an implantable VAD in 15%, and heart transplantation in 18%.

197 stcardiotomy shock in 37, graft failure post-heart transplantation in 22, and right ventricular failu

198 lation was the bridge to LVAD in 6.9% and to heart transplantation in 3.5% of patients.

199 use of HF and accounts for more than half of heart transplantation in adults and children worldwide.

200 heart from a donor with UCMD for orthotopic heart transplantation in adults or children.

201 echanical circulatory support as a bridge to heart transplantation in children with severe heart fail

202 thy is the leading cause of late death after heart transplantation in children.

203 The association of SED with survival after heart transplantation in England, where there is univers

204 ss issues related to kidney, liver, lung, or heart transplantation in older adults and to propose a r

205 to be cost-effective relative to nonbridged heart transplantation in specific circumstances.

206 CKD is a common complication of heart transplantation in the UK, and several risk factor

207 tation (BTT)-VAD approach relative to direct heart transplantation in transplant-eligible patients.

208 We used a model of combined bone marrow and heart transplantation, in which tolerance and stable chi

209 may reduce rates of CMV-related events after heart transplantation, including the incidence of acute

210 Health insurance status at heart transplantation influences recipient survival, but

211 ansplant acute kidney injury after liver and heart transplantation, integrating discussion of protein

212 Heart transplantation is a lifesaving procedure for pati

213 Heart transplantation is an established treatment for ad

214 Heart transplantation is an established, valuable therap

215 ition from private to public insurance after heart transplantation is associated with worse long-term

216 The field of heart transplantation is continually adapting to the gro

217 ldren with dilated cardiomyopathy listed for heart transplantation is not well defined.

218 her organs, but those available suggest that heart transplantation is safe in individuals with a hist

219 Heart transplantation is the most effective therapy for

220 Heart transplantation is the most effective therapy for

221 ne of the most promising new alternatives to heart transplantation is use of ventricular assist devic

222 Antifungal prophylaxis after heart transplantation is usually targeted to high-risk r

223 In advanced HF, the criteria for heart transplantation, left ventricular assist device, a

224 Potential heart transplantation/left ventricular assist device can

225 entricular function is uncommon in pediatric heart transplantation (<15% of all transplants), yet gra

226 was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard

227 During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, a

228 In severe cases, mechanical support or heart transplantation may become necessary.

229 Instead, referral for heart transplantation may offer their best chance at lon

230 function and size; 51% had died or undergone heart transplantation (median, 3.2 months), and 27% had

231 that in a fully mismatched heterotopic mouse heart transplantation model, T cells deficient for T-bet

232 attenuated graft rejection in a heterotopic heart transplantation model.

233 We used murine heart transplantation models to confirm that endothelial

234 e underlying conditions of the patients were heart transplantation (n = 3), corticosteroid-dependent

235 age 1 year or older, with a rate of death or heart transplantation of 3% (95% CI 1-5) at 2 years.

236 ypes also did poorly, with rates of death or heart transplantation of 45% (95% CI 32-58) at 2 years f

237 culatory support, and outcomes of orthotopic heart transplantation of these patients.

238 ardial activity in patients after orthotopic heart transplantation (OHT) and correlated it with patho

239 entricular (LV) dysfunction after orthotopic heart transplantation (OHT) is multifactorial and can be

240 Although orthotopic heart transplantation (OHT) remains the preferred treatm

241 otrope-dependent medical therapy, orthotopic heart transplantation (OHT), left ventricular assist dev

242 of morbidity and mortality after orthotopic heart transplantation (OHT).

243 tes from time of diagnosis to the earlier of heart transplantation or death for children in each subg

244 within 2 years of diagnosis later underwent heart transplantation or died.

245 heart failure (ie, requiring medications or heart transplantation or leading to death).

246 vanced heart failure patients at the time of heart transplantation or left ventricular assist device

247 nts with severe heart failure as a bridge to heart transplantation or recovery.

248 onary artery dissections, and 5 women needed heart transplantation or ventricular assist device impla

249 -0.97]), living alone (OR=2.78 [1.09-7.09]), heart transplantation (OR=3.49 [1.34-9.09]), and being o

250 omposite of all-cause mortality, listing for heart transplantation, or initiation of palliative care.

251 lantable cardioverter-defibrillators (ICDs), heart transplantation, or other therapeutic measures hav

252 ondary end points were a composite of death, heart transplantation, or readmission because of VT recu

253 om death, left ventricular assist device, or heart transplantation over 4 years.

254 R Z score was the only predictor of death/re-heart transplantation (P=0.003).

255 Heart transplantation recipients aged 2 to 40 years, tra

256 In heart transplantation, registry analyses have shown that

257 Treatment of acute rejection (AR) in heart transplantation relies on histopathological gradin

258 Heart transplantations remain rare owing to frequent inv

259 Wait-list mortality for children awaiting heart transplantation remains high.

260 ients, however, have been excluded from most heart transplantation research.

261 ABO-incompatible (ABOi) infant heart transplantation results in B-cell tolerance to gra

262 with heart failure or those with orthotopic heart transplantation, serum levels and endothelial expr

263 ifferent regions, the occurrence of death or heart transplantation showed no significant regional ass

264 m subjects with Chagas disease who underwent heart transplantation showed the expression of Gal-3 in

265 ficacy end point was a composite of death or heart transplantation, shunt thrombosis, or performance

266 nt with specific cell ablation and embryonic heart transplantation studies, we identified a unique se

267 he primary end point of all-cause mortality, heart transplantation, sudden cardiac death, and appropr

268 Heart transplantation survival is comparable to that of

269 defined as the occurrence of cardiac death, heart transplantation, survived sudden cardiac death, ve

270 isease are more likely to die while awaiting heart transplantation than men, white patients, and thos

271 sequencing and prioritizing advanced HF and heart transplantation therapeutic options in patients wi

272 ably less evidence is available in pediatric heart transplantation, though similar indications in the

273 a summary of the experimental studies on rat heart transplantation to illustrate changes that occur t

274 Mean time from heart transplantation to NMB reversal was 2.9 +/- 3.2 (m

275 To see where heart transplantation truly fits into the long term, sea

276 Heart transplantation using donor hearts adequately pres

277 urrence on the composite outcome of death or heart transplantation using VT recurrence as a time-vary

278 Outcomes among children undergoing heart transplantation vary by region.

279 on (n=187), the rate of in-hospital death or heart transplantation was 25.5% versus 0% in FM versus N

280 urring immediately post ablation on death or heart transplantation was 3.45 (2.33-5.11) in reference

281 ism, for whom the estimated rate of death or heart transplantation was 57% (95% CI 44-69) at 2 years.

282 The median time from recurrence to death or heart transplantation was 65 and 198.5 days in patients

283 Decreased graft loss in pediatric heart transplantation was associated with a higher degre

284 Net benefit from heart transplantation was evident across all estimates o

285 trophic cardiomyopathy, the risk of death or heart transplantation was greatest for those who present

286 Heart transplantation was performed in 12 patients with

287 rdiomyopathy subgroups, the risk of death or heart transplantation was significantly increased when t

288 Using a mouse model of MHC-mismatched heart transplantation, we report markedly protective eff

289 Factors associated with death or heart transplantation were determined for each interval.

290 echocardiograms; patients with simultaneous heart transplantation were excluded.

291 Orthotopic kidney and heterotopic heart transplantation were performed in different Lewis

292 ary angiography between 5 and 15 years after heart transplantation were recruited in this study.

293 Heterotopic Brown Norway-Lewis heart transplantations were performed to study acute car

294 ars to be associated with factors other than heart transplantation, which was equally prevalent in bo

295 he explanted hearts of 6 patients undergoing heart transplantation who had prospectively undergone CM

296 center for patients with a history of prior heart transplantation who underwent anesthesia including

297 AV) has an incidence of 43% at 8 years after heart transplantation with extremely limited treatment o

298 ricle palliation is a growing indication for heart transplantation with its own unique challenges.

299 ble and multivariable predictors of death or heart transplantation within each causal subgroup.

300 iomyopathy is the most common indication for heart transplantation worldwide, and coxsackie B viruses